SensoDetect adds Dr Fatimah to its medical advisory board to boost data collection and drive autism study

SensoDetect AB, a pioneer in the development of screening and objective decision-support tools for neurodevelopmental disorders, today announced the appointment of Dr. Fatimah Saeed Alahmari, MD, MBA, a distinguished Developmental and Behavioural Paediatrician, as its new Medical Advisor. This strategic appointment is central to SensoDetect’s initiative to build a robust, clinically validated dataset for its innovative technology, specifically within the Middle East and North Africa (MENA) region.

Dr. Alahmari’s exceptional career spans over two decades, marked by leadership roles within Saudi Arabia’s most prestigious healthcare institutions. Her current position as Clinical Lead of the Developmental and Behavioural Disorder Saudi National Program at the Ministry of Health, coupled with her consultancy roles at Dr. Sulaiman Al Habib Medical Group and the Eradah Mental Health Complex, provides SensoDetect with unparalleled access to clinical settings and patient populations essential for large-scale data acquisition.

“Dr. Alahmari is not just a clinician; she is a system-level leader,” said Dr. Atwa, Head of Clinical Research at SensoDetect. “Her active involvement in shaping national health programs and her direct connections to multiple hospital networks are invaluable. She will be instrumental in integrating the SensoDetect solution into clinical workflows, ensuring the data we collect is both high-quality and representative of real-world patient diversity.”

Dr. Alahmari’s resume underscores a perfect alignment with SensoDetect’s mission. She is a published researcher with recent work in the Saudi Medical Journal on interventions for autism spectrum disorder and the prevalence of obesity in ADHD. Her ongoing research, including studies on electronic device usage and ADHD symptoms, demonstrates her commitment to evidence-based, technologically advanced approaches to patient care. Furthermore, her role as an Ambassador in Saudi Arabia for The Patient-Centered Outcomes Research Institute (PCORI) highlights her dedication to improving healthcare outcomes through rigorous research.

“I am passionate about leveraging technology, including AI and machine learning, to enhance the future prospects of children with disabilities,” stated Dr. Fatimah Alahmari. “SensoDetect’s objective biomarker analysis has the potential to revolutionize the diagnostic process for autism and ADHD, reducing subjectivity and wait times. I am eager to contribute to this important work by facilitating clinical studies and data collection across my network of hospitals and clinics, ensuring the technology is validated to the highest standards for the benefit of children and families in the region, and beyond.”

This appointment signals a significant acceleration of SensoDetect’s clinical validation roadmap. Dr. Alahmari’s extensive network, including her affiliations with the Ministry of Health, National Guard Health Affairs, and leading private hospital groups, will enable the initiation of multi-site clinical studies. This is a critical step towards achieving regulatory approvals and demonstrating the efficacy of SensoDetect’s technology to healthcare providers and investors alike.

Note to Editors: Dr. Alahmari’s full biography, including her publications, leadership roles, and certifications, is available upon request.

For more information or partnership inquiries, please contact:

PA Hedin, CEO Sensodetect AB

+46 (0)46 15 79 04
pa.hedin@sensodetect.com

SensoDetect AB is a Med Tech AI company listed on the Spotlight Stock Market. The company was founded in Lund in 2005, based on more than 30 years of research in clinical psychoacoustics at the Department of Neuroscience at Lund University. Initially, the focus was on patients with schizophrenia, as auditory hallucinations are a common symptom of the disease. However, today, the company offers a variety of other services within the product areas of screening, diagnostics, medication, and health. The products are used in both private and public healthcare and schools, as a screening and complement to other observations in ADHD, schizophrenia, and autism assessments, in measuring the effects of medication, and in hearing screening. SensoDetect's unique and globally patented technology reduces the economic impact on healthcare and society while providing patients and their families with faster and more reliable results.

More info at https://www.sensodetect.com/